A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Summary
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participants must have an ECOG performance status of 0 to 1. * Participants must have measurable disease by RECIST v1.1 (radiologically measured by the Investigator). * Participants must have documented histologically or cytologically confirmed advanced, unresectable/metastatic solid tumors, including NSCLC, HNSCC, TNBC, and HR+/HER2- breast cancer. Exclusion Criteria: * Participants must not have untreated CNS metastases. Participants are eligible if CNS metastases have been treated and do not require immediate treatment or have been treated and have neurologically re…
Interventions
- DrugBMS-986517
Specified dose on specified days
Locations (19)
- Local Institution - 0033Irvine, California
- USC/Norris Comprehensive Cancer CenterLos Angeles, California
- Local Institution - 0021Orange, California
- UPMC Hillman Cancer CenterPittsburgh, Pennsylvania
- Sanford Cancer CenterSioux Falls, South Dakota
- START - Dallas Fort WorthFort Worth, Texas